The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Borrower

A••• B••••••••• S•••• F••••• I••

Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Also written as: A••• B••••••••• S•••• Parent, LP

Nothing material in the last 200 days. No dated change on record yet.

Mark path, consensus per quarter end
Q2 2025: 100¢Q3 2025: 100¢Q4 2025: 100¢Q1 2026: 100¢Q2 2026: 100¢100¢ · 100¢ · 100¢ · 100¢ · 100¢Q2 2025 to Q2 2026
Where each lender marks it, 0 points apart
100¢Consensus: 100¢A••••• D••• S•••••••• B••: 100¢M••••• F•••••••• I••••••••• C•••: 100¢100¢
Principal held
at least $42.6M
sum of BDC pieces, a lower bound
Fair value
$42.0M
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
2
2 on the latest quarter
Facilities
3
2 equity pieces beside them
Next maturity
Feb 5, 2031
no dated debt inside 24 months
On the tape since
Mar 31, 2025
latest Jun 30, 2026
Events
4
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
Every BDC piece · 10 positions across 2 lenderslargest principal first, with instrument and rate
BDCInstrumentPrincipalFair valueRate
A••••• D••• S•••••••• B••term loan first lien
Investment T••• F•••• L••• S•••••• D••• - T••• L••• I••••••• R••• S+500, 1.00% F•••• M••••
$14.7M$14.5M
100c
SOFR+500 bp
M••••• F•••••••• I••••••••• C•••term loan first lien
F•••• L••• S•••••• D••• - T••• L••• S•••+500, 1.00% F•••• M••••••• D••• 02/05/32
$10.5M$10.4M
100c
SOFR+500 bp
A••••• D••• S•••••••• B••delayed draw term loan first lien
Investment T••• F•••• L••• S•••••• D••• - D•••••• D••• I••••••• R••• S+500, 1.00% F•••• M•
$10.5M$10.3M
100c
SOFR+500 bp
M••••• F•••••••• I••••••••• C•••delayed draw term loan first lien
F•••• L••• S•••••• D••• – D•••••• D••• S•••+500, 1.00% F•••• M••••••• D••• 02/05/32
$6.9M$6.8M
100c
SOFR+500 bp
A••••• D••• S•••••••• B••equity equity
Investment T••• C••••• Equity - S••••
Not disclosed$1,000
100c
View all 10 positionslargest principal first
BDCInstrumentPrincipalFair valueRate
A••••• D••• S•••••••• B••preferred equity equity
Investment T••• P•••••••• Equity - P•••••••• S•••••
Not disclosed$99,000
100c
A••••• D••• S•••••••• B••revolver first lien
Investment T••• F•••• L••• S•••••• D••• - R••••••• I••••••• R••• S+500, 1.00% F•••• M•••••
Not disclosed$-107,000
92c
SOFR+500 bp
M••••• F•••••••• I••••••••• C•••equity equity
C••••• Equity - C••••• S••••
Not disclosed$1,000
100c
M••••• F•••••••• I••••••••• C•••revolver first lien
F•••• L••• S•••••• D••• – R••••••• S•••+500, 1.00% F•••• M••••••• D••• 02/05/31
Not disclosed$-34,000
87c
SOFR+500 bp
M••••• F•••••••• I••••••••• C•••preferred equity equity
P•••••••• Equity - P•••••••• Equity
Not disclosed$99,000
100c
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
FacilityHeldOn costPricingMaturityBDCs
first lien term loan first lienat least $25.2M100cSOFR+500 bpFeb 5, 20322
first lien delayed draw term loan first lienat least $17.4M100cSOFR+500 bpFeb 5, 20322
first lien revolver first lienunknownn/aSOFR+500 bpFeb 5, 20312
Equity pieces beside the debt: preferred equity ($198,000 fair value, 2 BDCs), equity ($2,000 fair value, 2 BDCs)
Through time
the borrower's pieces summed across BDCs, every quarter end
Quarter endBDCsPrincipal heldFair valueOn costPIK pieces
Jun 30, 20262$42.6M$41.8M100c0
Mar 31, 20262$42.7M$41.7M100c0
Dec 31, 20252$25.4M$24.4M99c0
Sep 30, 20252$25.5M$24.5M99c0
All 6 quarters
Quarter endBDCsPrincipal heldFair valueOn costPIK pieces
Jun 30, 20252$25.5M$24.5M99c0
Mar 31, 20252$25.5M$24.7M100c0
What changed
Every change including routine ones
Identity
Group key
AVID BIOSERVICES SPACEderivedthe codename stem after legal suffixes and deal words
Spellings
2 across 2 BDCsderived
Industry
Pharmaceuticalsreportedas one filer wrote it